The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

BACKGROUND: Colorectal carcinoma (CRC) with CpG island methylator phenotype (CIMP) is recognized as a distinct subgroup of CRC, and CIMP status affects prognosis and response to chemotherapy. Identification of CIMP status in CRC is important for proper patient management. In Eastern countries, howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Byung-Hoon, Bae, Jeong Mo, Lee, Eui Jin, Yu, Hong Suk, Kim, Young-Ho, Chang, Dong Kyung, Kim, Hee Cheol, Park, Cheol Keun, Lee, Suk-Hee, Kim, Kyoung-Mee, Kang, Gyeong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162585/
https://www.ncbi.nlm.nih.gov/pubmed/21827707
http://dx.doi.org/10.1186/1471-2407-11-344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162585/
https://www.ncbi.nlm.nih.gov/pubmed/21827707
http://dx.doi.org/10.1186/1471-2407-11-344

Ejemplares similares